Core Points - 60 Degrees Pharmaceuticals, Inc. has introduced a new 8-count bottle format for ARAKODA® (tafenoquine), aimed at patients traveling to malaria-endemic areas for shorter durations [1][2] - The new packaging option enhances accessibility for healthcare professionals prescribing ARAKODA for malaria prevention during trips of one week or less [2] - ARAKODA is the only weekly prophylactic therapy that protects against all stages of malaria for individuals aged 18 and older [3][4] Product Information - Tafenoquine, the active ingredient in ARAKODA, was discovered by the Walter Reed Army Institute of Research and received FDA approval for malaria prophylaxis in 2018 [4] - ARAKODA is available as a prescription-only medication and is distributed through pharmaceutical wholesaler networks in the U.S. and Australia [4] - The dosing regimen includes a loading phase of 2 x 100 mg tablets once daily for three days before travel, followed by 2 x 100 mg tablets weekly during travel, and 2 x 100 mg in the week following travel [4] Safety Information - ARAKODA is contraindicated in patients with G6PD deficiency, a history of psychotic disorders, or known hypersensitivity to tafenoquine [6][9] - The drug may cause serious adverse reactions, including hemolytic anemia and methemoglobinemia, necessitating monitoring and appropriate therapy [8][11] - Common adverse reactions reported include headache, dizziness, and gastrointestinal issues, with a notable incidence of psychiatric effects in susceptible individuals [11] Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing and marketing new medicines for infectious diseases, with a focus on malaria prevention [14] - The company was founded in 2010 and has received support from the U.S. Department of Defense and private investors [14] - The headquarters is located in Washington D.C., with a majority-owned subsidiary in Australia [14]